the sankyo team-up is not relenza but was loosely called relenza mk2; it is now identified as LANI ( long action neuramidase inhibitor) the product is now in phase 1 trial and is own 50/50 by bta/sankyo
- Forums
- ASX - By Stock
- BTA
- good angle on lawsuit
good angle on lawsuit, page-5
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)